Research article

Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency

Alban Gervais1, Jean Levêque1,2, Françoise Bouet-Toussaint1,3, Florence Burtin4, Thierry Lesimple5, Laurent Sulpice6, Jean-Jacques Patard1,7, Noelle Genetet1,8 and Véronique Catros-Quemener1,3

1Groupe de Recherche en Thérapeutique AntiCancéreuse, UPRES 2261, Faculté de Médecine de Rennes, Rennes, France
2Service de Gynécologie, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Rennes, France
3Laboratoire de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France
4Laboratoire d’Anatomo-Pathologie, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France
5Service d’Oncologie Médicale, Centre AntiCancéreux de Rennes, Avenue de la Bataille Flandres-Dunkerque, Rennes, France
6Département de Chirurgie Viscérale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France
7Service d’Urologie, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France
8Laboratoire d’Immunologie, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes, France

Corresponding author: Véronique Catros-Quemener, veronique.catros@chu-rennes.fr

Received: 11 Aug 2004 Revisions requested: 21 Sep 2004 Revisions received: 26 Nov 2004 Accepted: 18 Jan 2005 Published: 25 Feb 2005

Breast Cancer Research 2005, 7-R326-R335 (DOI 10.1186/bcr1001)

This article is online at: http://breast-cancer-research.com/content/7/3/R326

© 2005 Gervais et al.; licensee BioMed Central Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Dendritic cells (DCs) are antigen-presenting cells that are currently employed in cancer clinical trials. However, it is not clear whether their ability to induce tumour-specific immune responses when they are isolated from cancer patients is reduced relative to their ability in vivo. We determined the phenotype and functional activity of DCs from cancer patients and investigated the effect of putrescine, a polyamine molecule that is released in large amounts by cancer cells and has been implicated in metastatic invasion, on DCs.

Methods The IL-4/GM-CSF (granulocyte–macrophage colony-stimulating factor) procedure for culturing blood monocyte-derived DCs was applied to cells from healthy donors and patients (17 with breast, 7 with colorectal and 10 with renal cell carcinoma). The same peroxide-treated tumour cells (M74 cell line) were used for DC pulsing. We investigated the effects of stimulation of autologous lymphocytes by DCs pulsed with treated tumour cells (DC-Tu), and cytolytic activity of T cells was determined in the same target cells.

Results Certain differences were observed between donors and breast cancer patients. The yield of DCs was dramatically weaker, and expression of MHC class II was lower and the percentage of HLA-DRLin- cells higher in patients. Whatever combination of maturating agents was used, expression of markers of mature DCs was significantly lower in patients. Also, DCs from patients exhibited reduced ability to stimulate cytotoxic T lymphocytes. After DC-Tu stimulation, specific cytolytic activity was enhanced by up to 40% when DCs were from donors but only up to 10% when they were from patients. IFN-γ production was repeatedly found to be enhanced in donors but not in patients. By adding putrescine to DCs from donors, it was possible to enhance the HLA-DRLin- cell percentage and to reduce the final cytolytic activity of lymphocytes after DC-Tu stimulation, mimicking defective DC function. These putrescine-induced deficiencies were reversed by treating DCs with all-trans retinoic acid.

Conclusion These data are consistent with blockade of antigen-presenting cells at an early stage of differentiation in patients with breast cancer. Putrescine released in the microenvironment of DCs could be involved in this blockade. Use of all-trans retinoic acid treatment to reverse this blockade and favour ex vivo expansion of antigen-specific T lymphocytes is of real interest.

ATRA = all-trans retinoic acid; CTL = cytolytic T lymphocyte; DC = dendritic cell; DC-Tu = DCs pulsed with treated tumour cells; GM-CSF = granulocyte–macrophage colony-stimulating factor; IFN = interferon; IL = interleukin; MHC = major histocompatibility complex; MNC = mononuclear cell; NK = natural killer; TA = tumour antigen.
Introduction
The role played by T cell mediated immunity in the control of tumour growth has been established over recent years. As a result, most immunization strategies adopted in clinical trials of cancer treatments have aimed at enhancing tumour antigen (TA)-specific cellular immunity. The induction and expansion of TA-specific T cells requires optimal antigen presentation and T-cell co-stimulation. Dendritic cells (DCs) are specialized antigen-presenting cells with a remarkable ability to stimulate naive T lymphocytes and generate memory T lymphocytes [1]. However, objective response rates to vaccine or DC trials in cancer remain low [2]. Differentiation and maturation of DCs are important to their protective activity against tumour development [3]. Exposure to necrotic tumor cells can induce maturation of immunostimulatory DCs [4] but the involved mechanisms are still unresolved [5].

Cytotoxic T lymphocytes (CTLs) directed against tumour cells can be amplified in vitro with the use of DCs pulsed with treated tumour cells (DC-Tu) [6]. When assays were done with cells from healthy donors, DC-Tu stimulation repeatedly increased the final cytolytic activity of T cells more than two-fold. However, we observed that a similar procedure applied to cells from cancer patients enhanced the final cytotoxic activity against autologous tumour only in half of the assays [6]. We noticed in these experiments that the final yield and phenotype of blood-derived myeloid immature DCs was heterogeneous in cancer patients [6]. These findings could be related to a relationship between immune suppression instilled during tumour development, as previously described by Kusmartsev and Gabriovich [7], and increased production of immature myeloid cells in patients with advanced cancers [8].

Our aim in the present study was to detail the differences in characteristics of DCs between patients with cancer and healthy donors. We investigated blood cells from patients with breast, colorectal, or renal carcinoma and compared them, using the same assays, with cells from healthy donors. DCs were obtained from peripheral blood [9] and matured using various cocktails combining proinflammatory cytokines and danger or co-stimulating signals that are known for their ability to induce a T-helper-1 phenotype [3,10]. Tumour cells were from the M74 melanoma cell line in all of the assays. Treatment of tumour cells was done for induction of late apoptosis (postapoptotic necrotic tumour cells) [11]. Necrotic cells were chosen for DC pulsing, in accordance with previous reports [5,12,13] and preliminary experiments by our group that demonstrated that processing and cross-presentation of TA led to specific CTL responses in DCs pulsed under these conditions (Gervais A, unpublished data).

The ultimate mechanisms by which DC deficiency is established are not understood. The tumour microenvironment is rich in growth factors and molecules that are able to modulate the immune response of the host. Polyamines, which are conducive to proliferation and metastatic invasion, are synthesized in large amounts by tumour cells [14]. A therapeutic strategy combining inhibition of all cellular and exogenous sources of polyamines has been evaluated in several murine tumour models, with positive findings [15]. However, the role played by polyamines in immune processes is poorly understood [16,17]. Nevertheless, our group showed that polyamine deprivation can prevent the development of in vivo tumour-induced immunosuppression [18]. In the present study, the hypothesis that putrescine is involved in immunodeficiency was tested by investigating the effects of putrescine on functional activity of DCs from donors. This treatment was able to mimic the abnormalities observed in DCs from patients with breast cancer.

Materials and methods
Patients
Thirty-four patients with histologically confirmed cancer were enrolled in the study. Seventeen (age 47–76 years) had breast cancer: 13 had infiltrating ductal carcinoma (grade I-III; Elston Ellis grading); one was invasive lobular carcinoma (grade III); one was mixed ductal-lobular carcinoma (grade I); and two were in situ ductal carcinomas (low and high grade). Seven (age 33–86 years) had colorectal cancer (stage 2–4 adenocarcinoma) and 10 (age 42–78 years) had renal cell carcinoma (Fuhrman grade III clear cell carcinoma). Patients were newly diagnosed and peripheral blood samples were collected at the time of initial surgery, with no prior therapy. The study was approved by the regional ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Rennes, Rennes, France). Eleven healthy volunteers (HLA-A2) served as control individuals (Etablissement Français du Sang, Rennes, France).

Isolation of cells from peripheral blood
Cells were centrifuged by applying a density gradient (UNISEP®; Novamed, Jerusalem, Israel). Mononuclear cells (MNCs) were frozen in human serum albumin and 10% dimethyl sulfoxide until use for DC and lymphocyte preparation.

Tumour cell treatment
The HLA-A2 MelanA-Mart1 expressing M74 melanoma cell line was used for both antigen DC pulsing and as a target for evaluation of specific cytotoxic activity. This cell line and the K562 natural killer (NK) cell-sensitive erythroleukaemia cell line were maintained in RPMI 1640 medium (Eurobio, Les Ulis, France) containing 10% foetal calf serum (Gibco Invitrogen Life Technologies, Cergy Pontoise, France), 1 mmol/l L-glutamine, 50 µg/ml streptomycin and 50 IU/ml penicillin (ICN Biomedicals, Aurora, OH, USA). M74 cells were used for TA DC pulsing following necrosis-inducing treatment. The method was adapted from that presented by Lennon and coworkers [11]. Briefly, cells were treated with hydrogen peroxide 10 µmol/l (Sigma-Aldrich,
Saint Quentin-Fallavier, France) for 3 consecutive days. Supernatant cells were collected each day, pooled and kept at 4°C. Collected cells (M74 per) were used for DC pulsing (DC-Tuper).

Treated tumour cells were examined for degree of apoptosis and secondary necrosis using a standard fluorescence-activated cell sorting assay (Annexin V-FITC detection kit; Immunotech, Marseille, France), which detects binding of annexin V (A) and propidium iodide inclusion/exclusion. With 10 µmol/l peroxide, 16% of the collected cells were apoptotic (annexin V positive/propidium iodide negative) and 50% were in a state of postapoptotic necrosis (annexin V positive/propidium iodide positive).

**Culture of dendritic cells**

DCs were prepared from MNCs (from patients or healthy donors) in accordance with the method described by Sallusto and Lanzavecchia [8]. Briefly, 10 x 10^6 MNCs were seeded in 5 ml serum-free X-Vivo 10 medium (Biowhittaker, Walkersville, MD, USA) in a 25 cm² culture flask (Cellstar®; Greiner Labortechnik, Frickenhausen, Germany). Nonadherent cells were collected after 2 hours for lymphocyte culture. The remaining adherent cells were cultured in DC medium: serum free X-Vivo 10 medium supplemented with 10% AB serum (EFS de Rennes, Rennes, France), 10 µg/ml steptomycin and 100 IU/ml penicillin. Granulocyte–macrophage colony-stimulating factor (GM-CSF) 1000 IU/ml (Leucomax 400™; Novartis/Shering Plough, Huringue, France, Switzerland) and 400 IU/ml IL-4 (Promokine; Promocell, Heidelberg, Germany) were added on days 0, 2 and 5 of culture. After 7 days nonadherent cells were collected and added to peroxide-treated M74 cells (ratio 1:10) for antigen processing. For maturation assays, immature DCs were seeded in DC medium: serum free X-Vivo 10 medium supplemented with 10% AB serum, 1 mmol/l L-glutamine, 2% pyruvate, 1% nonessential amino acids (Bio-Whittaker, Walkersville, MD, USA) in a 25 cm² culture flask (Cellstar®; Greiner Labortechnik, Frickenhausen, Germany). Immature DCs from patients and donors and opsonized bacteria were co-cultured for 2 hours at 37°C and their internalization was evaluated by flow cytometry, in accordance with the manufacturer’s recommendations. Controls were run at +4°C.

**Phagocytic activity of dendritic cells**

Phagocytic activity was evaluated using FITC-labelled opsonized bacteria (Escherichia coli; Phago Test®; OrpeGen Pharma, Heidelberg, Germany). Immature DCs from patients or donors and opsonized bacteria were co-cultured for 2 hours at 37°C and their internalization was evaluated by flow cytometry, in accordance with the manufacturer’s recommendations. Controls were run at +4°C.

**IL-10 and IL-12 production**

Measurements of IL-10 and IL-12 were done in supernatants of immature DCs and mature DCs after 72 hours in culture at 37°C. Assays were done using enzyme-linked immunosorbent assay methods according to the manufacturer’s instructions (Ready-set-Go®, eBioscience, San Diego, CA, USA) and were performed in duplicate.

**Lymphocyte culture**

Lymphocytes were cultured from MNCs in lymphocyte medium: RPMI 1640 containing 10% AB serum, 1 mmoll/l L-glutamine, 2% pyruvate, 1% nonessential amino acids (Bioproducts, Gagny, France), 100 µg/ml streptomycin, 100 IU/ml penicillin and 150 IU/ml IL-2 (Proleukin®; Chiron, Suresnes, France). After 8 days in culture (density 10⁶ cells/ml), lymphocytes were stimulated with DC-Tuper. Number, phenotypic and functional characteristics of lymphocytes were evaluated 7 days after DC-Tuper stimulation. Viability was evaluated using the trypan blue exclusion test. Controls were performed with nonstimulated lymphocytes.

**Flow cytometry analysis**

Cells (10⁵) were suspended in phosphate-buffered saline supplemented with 0.5% bovine serum albumin and labelled for characterization of lymphocyte or DC phenotype by incubation at 4°C for 30 min with the following PE-, FITC-, or PC5-conjugated antibodies and corresponding isotypes: anti-CD3 (clone UCHT1), anti-CD4 (13B8.2), anti-CD8 (B9.11), anti-CD25 (B1.49.9), anti-CD40 (mAb 89), anti-CD56 (NKH-1), anti-αβ-TCR (BMA 031), anti-γδ-TCR (immu 510), anti-CD80 (MAB 104), anti-CD83 (HB15A) and anti-CD154 (CTLA-4; after saponin permeabilization) from Immunotech (Marseille, France); anti-CD11c (S-HCL-3), anti-HLA-DR (L243) and
Lin1 cocktail (anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20 and anti-CD56) from Becton Dickinson/Pharmin-
gen (CA, USA); and CD86 (BU63) from Immunotech (Oxford, UK). Cells were washed and suspended in 250 µl phosphate-
buffered saline added with 0.3% formol. CD4+CD25+CTLA4+ was considered to be the T regulatory cell phenotype, in accordance with the findings of Jonuleit and coworkers [19].

Data analysis was performed using a FACScan flow cytometer (Becton Dickinson).

Cytotoxicity assays

T-cell mediated cytotoxicity was tested in triplicate with a standard 51Cr release assay. The assays were conducted in U-
bottomed microtitre plates. Depending on the assays, target cells were M74 tumour cell line or K562 cells pulsed with 51Cr ([51Cr]sodium chromate; Amersham Life Sciences, Bucking-
hamshire, England) for 1 hour.

A total of 5000 target cells/well were mixed with effector cells (ratio of effector to target cells 50:1) and incubated for 4 hours. Chromium release was assessed in culture superna-
tants using a γ-counter (Topcount, Packard Instrument, Rungis, France). Specific release was calculated as follows: 

\[
\frac{(\text{mean experimental counts/min} - \text{mean spontaneous counts/min})}{(\text{mean maximum counts/min} - \text{mean spontaneous counts/min})} \times 100
\]

IFN-γ production

Responder cells were evaluated for their production of IFN-γ in response to contact with antigenic cells. Analyses were per-
fomed 8 days after stimulation with DC-Tuper. Briefly 2 × 10^6 M74 cells were seeded in 24-well plates for 12 hours. The supernatant was discarded before adding 10^5 lymphocytes in a final volume of 500 µl of medium without IL-2. The plates were then incubated at 37°C for 72 hours and IFN-γ was measured in supernatant using enzyme-linked immunosorbernt assay methods, in accordance with the manufacturer’s instructions (Ready-set-Go®; eBioscience). Duplicate wells were run for each assay.

Table 1

| DC source                        | DC yield (%) |
|----------------------------------|--------------|
| Healthy donors (n = 8)            | 12.5 ± 5.0   |
| Patients with colorectal cancer (n = 4) | 5.9 ± 2.6   |
| Patients with breast cancer (n = 6) | 3.1 ± 1.2*  |

Peripheric blood mononuclear cells (PBMCs) were cultured with granulocyte–macrophage colony-stimulating factor and IL-4. Data presented are the dendritic cell (DC) yield after 7 days: number of CD11c+Lin cells/number of PBMCs at day 0. DCs were prepared from blood of healthy donors, patients with colorectal cancer, or patients with breast cancer. *P < 0.01 versus donors.

Statistical analysis

Each assay was repeated with at least three different donors or patients. The nonparametric Mann–Whitney rank test was used for statistical analysis.

Results

Yield and characteristics of dendritic cells

After 7 days in culture with GM-CSF and IL-4, a mean of 12.5% of the blood MNCs from healthy donors differentiated into immature DCs (Table 1). These cells were predominantly HLA-DR+CD11c+ (94 ± 4%) and CD11c+Lin- (87 ± 13 %), which is characteristic of myeloid DCs. The yield of immature DCs was reduced after the same procedure was conducted in MNCs from patients with cancer (Table 1), and this reduction was significant for MNCs from patients with breast cancer. These patients had normal blood monocyte counts (0.44 ± 0.09 Giga/l). Furthermore, immature DCs prepared from peripheral blood MNCs from breast cancer patients expressed high levels of CD11c (79 ± 14% CD11c+Lin-), but large individual differences in HLA-DR expression were recorded. The percentages of HLA-DR+Lin- cells were signifi-
cantly reduced and HLA-DR-Lin+ significantly increased in patients with breast cancer (Fig. 1).

This latter observation led us to focus our DC investigations on breast cancer patients. On comparing the expressions of CD40, CD83 and CD86 on immature DCs between healthy donors (n = 6) and patients with breast cancer (n = 10), no significant differences were observed (CD40: 87 ± 7% versus 78.5 ± 16%, respectively; CD83: 6 ± 6% versus 10 ± 10%; and CD86: 82 ± 14% versus 69 ± 22%). For patients with colorectal cancer or renal cell carcinoma, percentages of HLA-DR+Lin- cells in DCs were not significantly enhanced when compared with those for healthy donors (Fig. 1).

The phagocytic capacity of immature DCs from breast cancer patients was similar to that of immature DCs from healthy donors (respectively; at 37°C: 42 ± 9% and 44 ± 15%; and at 4°C: 5 ± 1% and 2 ± 1%). Mean fluorescence intensity after 2 hours of co-culture with FITC-labelled bacteria was 653 ± 56 and 656 ± 30 for patients and healthy donors, respectively.
Maturation of dendritic cells

For donors and patients, the three maturation cocktails induced significant increases in expression of CD80 and CD83 markers (Table 2, Fig. 2). However, the level of maturation reached by DCs was weaker for patients than for donors; whatever the combination of maturing agents used, we observed lesser expression of mature DC markers in patients (Fig. 2). For donors, high percentages of CD86- and CD40-expressing cells were similarly observed in immature and mature DCs (Table 2). These markers were heterogeneously expressed in patients. IL-10 and IL-12 production by immature DCs was similar in cells from donors and patients (Table 2). Interestingly, maturation induced by Ribomunyl®/Imukin® stimulated IL-12 production more for DCs from patients than for DCs from donors (Table 2).

Dendritic cell mediated T-cell stimulation

When lymphocytes were subjected to DC-Tu
per stimulation, expansion was observed. The Expanding Index was not significantly greater in healthy donors (7.5 ± 2; n = 7) than in cancer patients (5 ± 2.5; n = 5). However, contrary to our observations in healthy donors, the cytolytic activity of lymphocytes against the M74 cell line was not significantly enhanced after DC-Tu
per stimulation for breast cancer patients (Fig. 3), which indicates that DC-mediated T-cell stimulation was unsuccessful in the patients.

In addition, the basic cytotoxic activity of lymphocytes against the M74 cell line was significantly less for cancer patients than for healthy donors (Fig. 3). The differences persisted after DC-Tu
per stimulation. In contrast, nonspecific lysis of the natural killer (NK) cell sensitive K562 cell line remained unchanged after DC-Tu
per stimulation both for donors and for patients (respectively: from 51 ± 38% to 51 ± 25% lysis and from 19 ± 18% to 23 ± 23% lysis). Taken together, these observations suggest that TA-specific T cells were induced in donors but not in all of the breast cancer patients. No correlation could be established between reduced cytotoxic activity of lymphocytes from patients (against M74 or NK-sensitive cell lines) and percentage of regulatory T cells in the bulk (0.17 ± 0.14% CD4+CD25+CTLA4+ cells; n = 11).

Lymphocyte phenotype and IFN-γ production

Basic IFN-γ production in response to contact with M74 cells was similarly heterogeneous for lymphocytes from patients and those from donors. After DC-Tu
per stimulation, enhancement in IFN-γ production – a marker of T-helper-1 response – was consistently observed in lymphocytes from

**Table 2**

**Cell surface phenotype of immature and mature dendritic cells from breast cancer patients**

| Donors/patients | Immature DCs/mature DCs |
|----------------|-------------------------|
| **Healthy donors** | | |
| Donor | M13 | N14 | 015 |
| CD40 | 79/95 | 80/97 | 84/96 |
| CD80 | 0.1/90 | 1/97 | 8/91 |
| CD83 | 2/52 | 8/48 | 19/40 |
| CD86 | 85/98 | 68/98 | 57/97 |
| IL-10 | 43/46 | 47/214 | 89/112 |
| IL-12 | 5/400 | 7/29 | 5/182 |
| **Patients with breast cancer** | | |
| Patient | S219 | S221 | S222 |
| CD40 | 91/93 | 42/86 | 77/86 |
| CD80 | 3/84 | 4/76 | 4.5/72 |
| CD83 | 8/17 | 14/66 | 14/72 |
| CD86 | 87/89 | 25/86 | 68/89 |
| IL-10 | 46/0 | 57/132 | 30/63 |
| IL-12 | bdl/2154 | bdl/1280 | bdl/1261 |

Data are expressed as the percentage of HLA-DR+ cells expressing CD40, CD80, CD83 and CD86, and IL-10 and IL-12 production by dendritic cells (DCs) before and after maturation with cocktail C: Ribomunyl®/Imukin®. Data are individual values from patients S219, S221 and S222. Controls are from three different donors (M13, N14, O15). bdl, below the detection limit; DC, dendritic cell.
healthy donors (Table 3); this was in contrast to patients, for whom enhancement was seen only in two out of six assays. Considerable reduction in IFN-γ production was seen in lymphocytes from patient S137, indicating that autologous DCs were not immunogenic in the assay (Table 3). Phenotypic characterization revealed 71% HLA-DR-Lin- cells in DCs from patient S137.

Lymphocytes from donors and cancer patients were of similar phenotype after 15 days in culture with 150 UI IL-2 (Table 4). Of the cells, 70% were T lymphocytes and more than 50% were CD8+ T cells. Single stimulation with DC-Tu per did not changed the respective percentages of CD4+ T cell, CD8+ T cell, or γδ T cell subpopulations. In addition, the percentages of regulatory T cells remained similar after DC-Tu per stimulation, at 0–0.5% of cells.

**Influence of putrescine treatment on dendritic cell phenotype**

As shown in Fig. 1, of cells prepared from MNCs from donors according to the classic procedure for preparing immature DCs, a mean of only 4.6% had the HLA-DR-Lin- phenotype. An 18-hour treatment with 10 mmol/l putrescine increased this percentage to 29.5% (Fig. 4). Expression of other surface markers (CD40, CD80, CD83 and CD86) was not changed by putrescine treatment (data not shown). Putrescine was internalized by DCs because intracellular putrescine concentrations were dramatically enhanced after treatment (data not shown).

Maturation of dendritic cells (DCs) from healthy donors or from breast cancer patients. Data are expressed as the percentage of the cells (with standard error) expressing the CD80, CD83 and CD86 surface markers after treatment of immature DCs with a combination of maturing agents: (a) tumour necrosis factor (TNF)-α/lipopolysaccharide (LPS)/CD40L (n = 3); (b) IL-1β/IL-6/TNF-α/prostaglandin (PG)E2 (n = 4–5); and (c) Ribomunyl®/Imukin® (n = 3). *Different from corresponding donors in each individual assay.
When DCs were treated daily for 5 days with 1 \( \mu \)mol/l ATRA, the phenotypic change induced by putrescine was reversed (Fig. 4).

Putrescine-treated dendritic cells are defective in their ability to stimulate T cells

When DCs from donors were treated with putrescine, their ability to stimulate autologous T cells was significantly reduced. Following the DC-Tuper stimulation procedure, the Expanding Index of T cells declined by a mean 30 ± 11% when DCs were treated with putrescine (3.3 ± 1.9 versus 4.6 ± 2.5). In addition, specific cytolytic activity of DC-Tuper-stimulated lymphocytes was decreased when DCs were treated with putrescine (Fig. 5). This reduction was consistently observed in all donors (\( n = 6 \)). Treatment with ATRA reversed this putrescine-induced deficiency in DCs and restored cytolytic activity against M74 cells to normal values. A similar increase was repeatedly observed for all donors. These changes were not observed when the K562 target cells were used for nonspecific NK-type cytolytic activity (data not shown).

Discussion

In recent years several groups have described defective immune function in tumour-bearing animals [18,20,21] and in cancer patients [8,22,23]. Of note, it was reported that factors produced by tumour cells could influence differentiation of DCs from CD34+ progenitors, and that low concentrations of IL-4 could reverse the inhibitory effect of cancer cell conditioned medium, at least in terms of phenotype and some functional differentiation of DCs [22]. We show here that, even in the presence of IL-4, differences in differentiation of circulating cells...
monocytes into DCs persisted in cancer patients as compared with healthy donors. Using the classic procedure of blood monocyte derived DC culture (in the presence of IL-4 and GM-CSF), the ex vivo yield of DCs was found to be significantly reduced in patients with cancer, particularly in those with breast cancer. Furthermore, the phenotype of collected cells using this procedure was different in patients with breast cancer. Expression of MHC class II (HLA-DR+Lin- cells) was found to be lower and the percentage of HLA-DR -Lin- to be higher than in donors. In contrast, these subpopulations were not significantly modified in patients with colon or renal cell carcinoma.

Whatever combination of maturating agents was used, significantly lower expressions of mature DC markers were observed in patients with breast cancer. Maturation induced by Ribomunyl®/Imukin® resulted in lower expressions of CD80 and CD86 in patients than in donors, but, interestingly, it also resulted in greater production of IL-12.

Other groups have reported that, in breast cancer patients, monocyte-derived DCs have substantially lower level of expression of HLA-DR than do DCs isolated from control donors, leading to a reduced ability to stimulate allogenic and Flu-specific T-cell responses [8]. We confirm here that DCs from such patients not only exhibit low expression of MHC class II but they also have reduced ability to cross-prime exogenous antigens. Stimulation of CTLs by pulsed DCs was less efficient in patients than in donors. In a similar procedure for lymphocyte stimulation, using the same antigen preparation (peroxide-treated tumour cells) and tumour target (M74 cell line), we repeatedly observed defective stimulation when DCs were from patients with breast cancer. In general, the natural cytolytic activity of lymphocytes against the M74 or NK target cell line was found to be lower in patients than in donors.

Table 4

| Table 4 Phenotype of DC-Tuperi stimulated lymphocytes |
|------------------------------------------------------|
| Phenotype (%)                                      |
|           | Donor NSL | NSL + DC-Tuperi | Breast cancer NSL | NSL + DC-Tuperi |
| CD3+CD56 | 73 ± 30   | 76 ± 24         | 75 ± 17           | 73 ± 15         |
| CD3-CD56 | 6 ± 8     | 5 ± 6           | 10 ± 13           | 5 ± 5           |
| CD4+ T cell | 18 ± 21   | 18 ± 18         | 11 ± 5            | 20 ± 13         |
| CD8+ T cell | 28 ± 30   | 24 ± 27         | 29 ± 21           | 31 ± 22         |
| CD3+CD56 | 51 ± 21   | 57 ± 18         | 51 ± 19           | 59 ± 18         |
| TCR α/β  | 75 ± 23   | 77 ± 23         | 70 ± 20           | 83 ± 12         |
| TCR γ/δ  | 14 ± 15   | 13 ± 18         | 14 ± 11           | 11 ± 12         |

Cells are from healthy donors (n = 3) or breast cancer patients (n = 6). The percentage of positive cells for lymphocyte markers was measured in a 99% CD45+ population. Data are expressed as mean ± standard deviation. DC-Tu, dendritic cells pulsed with treated tumour cells; NSL, nonstimulated lymphocytes.

Figure 4

Effect of putrescine and all-trans retinoic acid (ATRA) on immature dendritic cell (DC) phenotype. Cells were collected after immature DC preparation procedure (imm DC; n = 11) and treated with 10 mmol/l putrescine (Put; n = 10). To putrescine-treated DCs was added 1 µmol/l ATRA (Put + ATRA; n = 5). Data are expressed as percentage of cells (with standard error) expressing the HLA-DR+Lin- and HLA-DR- Lin- phenotypes. *P < 0.01 versus imm DCs; **P < 0.02 versus putrescine-treated imm DCs.

Unlike donors, patients were not selected for their expression of HLA-A2 class I molecules. This could represent an advantage in terms of CTL activation, but the opposite was observed. Cytolytic activity was enhanced by up to 40% when DCs were from donors but only up to 10% when they were from patients.

IFN-γ production after DC-Tu stimulation was repeatedly found to be enhanced in donors. In contrast, nonspecific lysis of the
Defective DC function can be mimicked by adding putrescine to the culture medium of DCs from healthy donors. The percentage of cells with HLA-DR Low cells was found to be reduced after putrescine treatment in DCs, and concomitantly IFN-γ lymphocyte production was reduced twofold after DC-Tu stimulation, indicating that DCs were not only nonimmunogenic but were actually tolerogenic in this patient. However, the percentage of regulatory T cells was not changed after DC-Tu stimulation (<0.1% in S137). Correlation could not be demonstrated in this study between clinical grade of disease and HLA-DR Low DC phenotype. Defective function and poor ability of immature DCs to mature in some patients could represent an additional reason why DC cell therapy in cancer patients has, contrary to expectations, not yet yielded significant clinical responses [2].

In addition, breast cancer tissues are characterized by high polyamine levels. In a study including 174 patients with invasive breast cancer [27], a correlation was established between enhancement of putrescine and spermidine levels and tumour aggressiveness. Taken together, these observations led to the conclusion that putrescine release by tumour cells may be involved in the defective DC function observed in breast cancer patients. Interestingly, we showed in the present study that in vitro treatment of DCs with ATRA could reverse the putrescine-induced deficiency in DC function. ATRA and retinoic derivatives are known to influence DC differentiation, favouring a T-helper-1 response [28]. Further investigations are needed to detail the mechanism underlying the reversal in putrescine-induced deficiency in DC function. Nevertheless, use of ATRA treatment to initiate TA-specific CTL expansion in cancer patients could be of particular interest.

**Conclusion**

Taken together, our findings are in agreement with those from Gabrilovich and coworkers [7] on the contribution of immature myeloid DCs to cancer-induced immunosuppression—a mechanism that is involved in the escape of tumours from immune system control. Breast cancers are known frequently to over-express several TAs, such as carcinoembryonic antigen, MUC1, HER2/neu, P53 and members of the MAGE family, but little is known about detection of pre-existing T-cell responses, and the rationale for initiating vaccination strategies remains to be fully established. Nevertheless, a phase I clinical trial using vaccine prepared by fusing autologous tumor and DCs (32 patients included) [29] found that two patients with metastatic breast cancer exhibited disease regression. Our opinion is that future vaccination strategies could be improved in view of the present data. Procedures (established with cells from donors) must be adapted to the characteristics of the patient’s DCs. One simple treatment would be use ATRA to reverse blockade of DC function. The Ribomunyl®/Imukin® combination has demonstrated ability to induce DC maturation.
Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
AG carried out the DC-Tu preparation, lymphocyte stimulation procedures and measurements of functional activities, and participated in writing the manuscript. JL selected the patients with breast cancer and took biological samples. FB-T participated in the design and coordination of the study. FB carried out anatomo-pathological examinations. TL participated in drawing blood samples in breast patients. LS selected the patients with colonic carcinoma and took biological samples. J-JP selected the patients with renal cell carcinoma and took biological samples. NG carried out cytometric analyses. VC-Q conceived the study, participated in its design and coordination, and wrote the manuscript.

Acknowledgements
We thank C Thomas de La Pintière for technical assistance. This work was supported by grants from the Comité Grand Ouest de la Ligue Contre le Cancer.

References
1. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147.
2. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
3. Lutz MB, Schuler G: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002, 23:445-449.
4. Sauter B, Albert ML: Death-defying immunity: do apoptotic cells influence antigen processing and presentation. Nat Rev Immunol 2004, 4:223-231.
5. Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N, Toutirais O, Thirouard A-S, Ramée M-P, Chamaillard L, Catsos-Quemener V: Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for a cell therapy use. Cancer Immunol Immunother 2003, 52:699-707.
6. Kusmartsev S, Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002, 51:293-298.
7. Amand B, Clark JI, Nikitina E, Beynen Jv, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
8. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994, 179:1109-1118.
9. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B: Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002, 268:131-140.
10. Lennon SV, Martin SJ, Cotter TG: Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991, 24:203-214.
11. Spieker R, Chevalier P, Moreino N, Milpied N, Avet-Loiseau H, Harousseau JL, Melfah K, Gregoire M: Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002, 62:2861-2868.
12. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-89.
13. Cohen SS: A guide to the polyamines. In A Guide to the Polyamines New York: Oxford University Press; 1998:595.
14. Waj N: Polyamine deprivation in cancer. Cancer Immunol Immunother 1998, 44:17-14.
15. Chamaillard L, Catsos-Quemener V, Delcros J-G, Bansard J-Y, Havouis R, Desuy D, Moulinoux JP: Red blood cell polyamines, anaemia and tumor growth in the rat. Eur J Cancer 1996, 32A:316-321.
16. Schuler G, Schuler-Thurner B: The natural polyamines and the immune system. Prog Drug Res 1994, 43:87-141.
17. Vieweg V, Bansard JY, Delcros JG, Morillon M, Roth S, Havouis R, Desusy D, Moulinoux JP: Polyamine deprivation prevents the development of tumor-induced immune-suppression. Br J Cancer 1997, 76:365-370.
18. Jonuleit H, Schmitt E, Steinbrink K, Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001, 22:394-400.
19. Chamaillard L, Quemener V, Havouis R, Moulinoux J-P: Polyamine deprivation stimulates Natural killer cell activity in cancerous mice. Anticancer Res 1993, 13:1027-1034.
20. Bonnotte B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, Mercier F: Bcl2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998, 161:1433-1438.
21. Menetrier-Caux C, Thomachat MC, Albert L, Montmain G, Blay J-Y: IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Immunol Immunother 2004, 53:510-518.
22. Zhang M, Garagne T, Vrig H, Cohen P, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey K: Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med 1997, 185:1759-1768.
23. Ghringhelli F, Larmorier L, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344.
24. Chamaillard L, Catsos-Quemener V, Moulinoux J-P: Synergistic activation of macrophage activity by polyamine deprivation and cyclophosphamide. Anticancer Res 1997, 17:1059-1066.
25. Leveque J, Foucher F, Bansard J-Y, Havouis R, Graj J-Y, Moulinoux J-P: Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat 2000, 60:99-105.
26. Mothy M, Morbelli E, Iasonid J, Sauter B, WValueGenerationStrategy B, Gaugler B, Olive D: All-Trans retinoic acid skews monocyte differentiation into interleukin-12 secreting dendritic-like cells. Br J Haematol 2003, 122:829-836.
27. Avigan D, Asar B, Gong J, Barges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004, 10:4699-4708.